Literature DB >> 23933764

Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML.

C Ustun1, A C Wiseman, T E Defor, S Yohe, M A Linden, B Oran, M Burke, E Warlick, J S Miller, D Weisdorf.   

Abstract

Reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (allo-HCT) can cure patients with AML in CR. However, relapse after RIC allo-HCT may indicate heterogeneity in the stringency of CR. Strict definition of CR requires no evidence of leukemia by both morphologic and flow cytometric criteria. We re-evaluated 85 AML patients receiving RIC allo-HCT in CR to test if a strict definition of CR had direct implications for the outcome. These patients had leukemia immunophenotype documented at diagnosis and analyzed at allo-HCT. Eight (9.4%) had persistent leukemia by flow cytometric criteria at allo-HCT. The patients with immunophenotypic persistent leukemia had a significantly increased relapse (hazard ratio (HR): 3.7; 95% confidence interval (CI): 1.3-10.3, P=0.01) and decreased survival (HR: 2.9; 95% CI: 1.3-6.4, P<0.01) versus 77 patients in CR by both morphology and flow cytometry. However, the pre-allo-HCT bone marrow (BM) blast count (that is, 0-4%) was not significantly associated with risks of relapse or survival. These data indicate the presence of leukemic cells, but not the BM blast count affects survival. A strict morphologic and clinical lab flow cytometric definition of CR predicts outcomes after RIC allo-HCT, and therefore is critical to achieve at transplantation.

Entities:  

Mesh:

Year:  2013        PMID: 23933764     DOI: 10.1038/bmt.2013.124

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  18 in total

1.  Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

Authors:  Celalettin Ustun; Andreas Reiter; Bart L Scott; Ryotaro Nakamura; Gandhi Damaj; Sebastian Kreil; Ryan Shanley; William J Hogan; Miguel-Angel Perales; Tsiporah Shore; Herrad Baurmann; Robert Stuart; Bernd Gruhn; Michael Doubek; Jack W Hsu; Eleni Tholouli; Tanja Gromke; Lucy A Godley; Livio Pagano; Andrew Gilman; Eva Maria Wagner; Tor Shwayder; Martin Bornhäuser; Esperanza B Papadopoulos; Alexandra Böhm; Gregory Vercellotti; Maria Teresa Van Lint; Christoph Schmid; Werner Rabitsch; Vinod Pullarkat; Faezeh Legrand; Ibrahim Yakoub-Agha; Wael Saber; John Barrett; Olivier Hermine; Hans Hagglund; Wolfgang R Sperr; Uday Popat; Edwin P Alyea; Steven Devine; H Joachim Deeg; Daniel Weisdorf; Cem Akin; Peter Valent
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

2.  Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML.

Authors:  C Anthias; F L Dignan; R Morilla; A Morilla; M E Ethell; M N Potter; B E Shaw
Journal:  Bone Marrow Transplant       Date:  2014-02-10       Impact factor: 5.483

3.  Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD.

Authors:  Craig E Eckfeldt; Nicole Randall; Ryan M Shanley; Sophia Yohe; Nelli Bejanyan; Michelle Dolan; Erica D Warlick; Michael R Verneris; Claudio G Brunstein; John E Wagner; Daniel J Weisdorf; Celalettin Ustun
Journal:  Haematologica       Date:  2016-04-28       Impact factor: 9.941

4.  Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.

Authors:  Celalettin Ustun; Bryan J Trottier; Zohar Sachs; Todd E DeFor; Leyla Shune; Elizabeth L Courville; Shernan G Holtan; Michelle Dolan; Daniel J Weisdorf; Erica D Warlick
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-22       Impact factor: 5.742

5.  Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.

Authors:  Celalettin Ustun; Soyoung Kim; Min Chen; Amer M Beitinjaneh; Valerie I Brown; Parastoo B Dahi; Andrew Daly; Miguel Angel Diaz; Cesar O Freytes; Siddhartha Ganguly; Shahrukh Hashmi; Gerhard C Hildebrandt; Hillard M Lazarus; Taiga Nishihori; Richard F Olsson; Kristin M Page; Genovefa Papanicolaou; Ayman Saad; Sachiko Seo; Basem M William; John R Wingard; Baldeep Wirk; Jean A Yared; Miguel-Angel Perales; Jeffery J Auletta; Krishna V Komanduri; Caroline A Lindemans; Marcie L Riches
Journal:  Blood Adv       Date:  2019-09-10

6.  Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index.

Authors:  Fiona He; Qing Cao; Aleksandr Lazaryan; Claudio Brunstein; Shernan Holtan; Erica Warlick; Celalettin Ustun; Brian McClune; Mukta Arora; Armin Rashidi; Craig Eckfeldt; Daniel J Weisdorf; Nelli Bejanyan
Journal:  Biol Blood Marrow Transplant       Date:  2017-05-15       Impact factor: 5.742

7.  Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type.

Authors:  Erica D Warlick; Regis Peffault de Latour; Ryan Shanley; Marie Robin; Nelli Bejanyan; Alienor Xhaard; Claudio Brunstein; Flore Sicre de Fontbrune; Celalettin Ustun; Daniel J Weisdorf; Gerard Socie
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-06       Impact factor: 5.742

8.  Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up.

Authors:  Erica Dahl Warlick; Todd E DeFor; Nelli Bejanyan; Shernan Holtan; Margaret MacMillan; Bruce R Blazar; Kathryn Dusenbery; Mukta Arora; Veronika Bachanova; Sarah Cooley; Aleksandr Lazaryan; Philip McGlave; Jeffrey S Miller; Armin Rashidi; Arne Slungaard; Gregory Vercellotti; Celalettin Ustun; Claudio Brunsein; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2018-08-01       Impact factor: 5.742

9.  Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission.

Authors:  Joan How; Kiran R Vij; Maryam Ebadi; Todd E DeFor; Rizwan Romee; Michelle M Dolan; Celalettin Ustun; Daniel J Weisdorf; Michael A Linden; Armin Rashidi
Journal:  Am J Hematol       Date:  2018-10-09       Impact factor: 10.047

10.  Novel disease burden assessment predicts allogeneic transplantation outcomes in myelodysplastic syndrome.

Authors:  B J Trottier; Z Sachs; T E DeFor; L Shune; M Dolan; D J Weisdorf; C Ustun; E D Warlick
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.